Therefore, we speculate that drugs that can simultaneously regulate FXR and PXR/CAR or FXR and non-bile acid receptor targets may be more promising for the treatment of cholestatic liver disease. This evidence concerns the gene NR1I3 and Cholestatic liver disease.